Douglas L. Seidner

Douglas L. Seidner

Auto-generated profile, based on publicly available information

Douglas L. Seidner

Digestive Disease and Surgical Institute, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 9500 Euclid Ave./A51, Cleveland, OH 44195, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
DSDouglas L. Seidner
Douglas L. Seidner
BLBret A. Lashner
Bret A. Lashner
ABAaron Brzezinski
Aaron Brzezinski
PBPhillip L.C. Banks
Phillip L.C. Banks
JGJohn Goldblum
John Goldblum
SDStephen J. Demichele
Stephen J. Demichele

1 September 2002 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
DSDouglas L. Seidner
Douglas L. Seidner

1 June 2021 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
KCKristina Chen
Kristina Chen
FJFrancisca Joly
Francisca Joly
FMFan Mu
Fan Mu
SKSneha S. Kelkar
Sneha S. Kelkar
COClement Olivier
Clement Olivier
DSDouglas L. Seidner
Douglas L. Seidner
This study aimed to identify predictors and estimate time to teduglutide response among adult patients with short bowel syndrome with intestinal failure (SBS-IF) dependent on parenteral support (PS). Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension. Response was defined as ≥20% PS volume reduction from baseline for two consecutive visits. Early responders experienced the reduction at 20 and 24 weeks during STEPS while late responders experienced the reduction during STEPS-2. Timing and predictors for response were assessed among the treated population using Cox proportional hazard model. Time to response was compared in aetiological subgroups using Kaplan-Meier analysis. Patient characteristics and time to response were compared between early vs. late responders. A total of 34 patients were included in this analysis; overall median time to response was 4.3 months. The presence of stoma predicted a positive response to teduglutide (hazard ratio [HR]: 5.6; 95% confidence interval [CI]: 1.4-21.9; p = 0.013). Vascular disease (vs. inflammatory bowel disease [IBD]) as cause of major intestinal resection (HR: 0.2; 95% CI: 0.0-0.8; p = 0.015), presence of ileocecal valve (HR: 0.1; 95% CI: 0.0-0.8; p = 0.047), and female sex (HR: 0.3; 95% CI: 0.1-1.0; p = 0.026) are negatively associated with response. In subgroup analyses, patients with IBD (vs. vascular disease), with (vs. without) a stoma, and without (vs. with) colon-in-continuity had a shorter time to response (all p < 0.05). The mean times to response were 3.6 (standard deviation (SD): 1.1) months for early responders (n = 27) and 10.0 (SD: 6.1) months for late responders (n = 7). Fewer early responders had colon-in-continuity (51.9%) and ileocecal valve (0.0%) compared to late responders (100% and 28.6%, respectively; both p < 0.05). Early responders had a lower mean percentage of colon remaining compared to late responders (24.6% vs. 57.1%, respectively; p = 0.016). Time to response to teduglutide depends on bowel anatomy and SBS-IF aetiology. IBD, presence of a stoma, and absence of ileocecal valve were associated with earlier response to teduglutide. These findings may enhance management of patients with SBS-IF; however, due to sample size limitations, additional studies are needed to confirm these findings.

1 March 2006 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Open access
PDF file
DSDouglas L Seidner
Douglas L Seidner